Compare EXP & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXP | BLCO |
|---|---|---|
| Founded | 1963 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Building Materials | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 1994 | 2022 |
| Metric | EXP | BLCO |
|---|---|---|
| Price | $173.11 | $15.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $226.44 | $18.55 |
| AVG Volume (30 Days) | ★ 400.7K | 396.8K |
| Earning Date | 01-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 1.18 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | $495,023,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $1.84 | $8.63 |
| Revenue Next Year | $1.69 | $5.58 |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $175.59 | $10.45 |
| 52 Week High | $243.64 | $18.92 |
| Indicator | EXP | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 21.01 | 33.91 |
| Support Level | N/A | $14.39 |
| Resistance Level | $239.71 | $17.66 |
| Average True Range (ATR) | 5.68 | 0.52 |
| MACD | -2.66 | -0.21 |
| Stochastic Oscillator | 2.54 | 4.95 |
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.